<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010069356">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Sripan, Patumrat</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Le Coeur, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ingsrisawang, L.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Cressey, T. R.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Bouazza, N.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Foissac, F.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Ngo-Giang-Huong, Nicole</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Traisathit, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Srirompotong, U.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ayudhaya, O. P. N.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Puangsombat, A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Jungpipun, J.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Jittayanun, K.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Treluyer, J. M.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Jourdain, Gonzague</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Lallemant, Marc</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Urien, S.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy</title>
        <secondary-title>Antiviral Therapy</secondary-title>
      </titles>
      <pages>435-440</pages>
      <keywords>
        <keyword>THAILANDE</keyword>
      </keywords>
      <dates>
        <year>2016</year>
      </dates>
      <call-num>fdi:010069356</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Antiviral Therapy</full-title>
      </periodical>
      <isbn>1359-6535</isbn>
      <accession-num>ISI:000396089500008</accession-num>
      <number>5</number>
      <electronic-resource-num>10.3851/imp3001</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010069356</url>
        </related-urls>
        <pdf-urls>
          <url>https://www.documentation.ird.fr/intranet/publi/2017/04/010069356.pdf</url>
        </pdf-urls>
      </urls>
      <volume>21</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Background: Antiretroviral (ARV) regimens used for the prevention of mother-to-child transmission of HIV have evolved over time. We evaluated the contribution of different ARV regimens on the reduction of the plasma HIV RNA viral load (VL) during pregnancy. Methods: A total of 1,833 VL measurements from ARV-naive pregnant women participating in perinatal prevention trials in Thailand were included. Women received either zidovudine (ZDV) monotherapy, ZDV plus lopinavir/ritonavir (LPV/r), or ZDV plus lamivudine (3TC) plus LPV/r. VL time-course during pregnancy was described as a function of pretreatment VL and treatment duration using an E max non-linear mixed-effect model. VL reduction and median time to achieve a VL&lt; 50 copies/ml were estimated for each regimen. Results: Among 745 women, 279 (37%), 145 (20%) and 321 (43%) received ZDV monotherapy, ZDV+ LPV/r and ZDV+ 3TC+ LPV/r, respectively. The predicted VL reduction from baseline to delivery after a median of 10 weeks of treatment were 0.5, 2.7 and 2.9 log 10 copies/ml with ZDV monotherapy, ZDV+ LPV/r and ZDV+ 3TC+ LPV/r, respectively. At delivery, 1%, 57% and 63% of women receiving ZDV monotherapy, ZDV+ LPV/r or ZDV+ 3TC+ LPV/r had a VL&lt; 50 copies/ml. The addition of 3TC to ZDV+ LPV/r reduced the time to achieve a VL&lt; 50 copies/ml and the higher the pretreatment VL, the larger the effect 3TC had on reducing the time to VL&lt; 50 copies/ml. Conclusions: The addition of 3TC to ZDV+ LPV/r was associated with a slight further VL reduction but the time to reach a VL&lt; 50 copies/ml was shorter. This beneficial effect of 3TC is crucial for prevention of mother-to-child transmission in women who receive ARVs late and with high pretreatment VL.</abstract>
      <custom6>052 ; 050</custom6>
      <custom1>UR174</custom1>
      <custom7>Thaïlande</custom7>
    </record>
  </records>
</xml>
